CLINICAL TRIALS PROFILE FOR TETANUS AND DIPHTHERIA TOXOIDS ADSORBED

All Clinical Trials for tetanus and diphtheria toxoids adsorbed

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00707148 ↗	Pertussis Vaccine in Healthy Pregnant Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2009-01-01	The purpose of this study is to look at the safety and immunogenicity of a combination vaccine that includes tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). The study will be conducted in 48 pregnant women and 32 non-pregnant women. Safety of the newborn infant and the effect of the mother's vaccination on the infants' immune responses prior to vaccinating infants with another combination vaccine to protect against diphtheria, tetanus, and pertussis will be evaluated. Participants will be 18-45 years old. Pregnant volunteers will be 30-32 weeks pregnant and at a low risk for pregnancy complications. Pregnant volunteers will receive 2 injections (1 vaccine and 1 placebo, inactive substance); non-pregnant volunteers will receive 1 injection of vaccine. Blood samples will be collected from the mother and infant, along with the baby's growth measurements. Participation for mother infant pairs is about 15 months and about 7 months for non-pregnant women.
NCT02193347 ↗	IDH1 Peptide Vaccine for Recurrent Grade II Glioma	Active, not recruiting	Gary Archer Ph.D.	Phase 1	2016-01-28	Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).
NCT02529072 ↗	Nivolumab With DC Vaccines for Recurrent Brain Tumors	Completed	Bristol-Myers Squibb	Phase 1	2016-01-01	Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
NCT02529072 ↗	Nivolumab With DC Vaccines for Recurrent Brain Tumors	Completed	Duke Cancer Institute	Phase 1	2016-01-01	Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.

Clinical Trial Conditions for tetanus and diphtheria toxoids adsorbed

Condition Name

Condition Name for tetanus and diphtheria toxoids adsorbed
Intervention	Trials
Glioblastoma	2
Malignant Glioma	1
Pertussis	1
Astrocytoma	1

Condition MeSH

Condition MeSH for tetanus and diphtheria toxoids adsorbed
Intervention	Trials
Glioma	2
Glioblastoma	2
Brain Neoplasms	2
Tetanus	1

Clinical Trial Locations for tetanus and diphtheria toxoids adsorbed

Trials by Country

Trials by Country for tetanus and diphtheria toxoids adsorbed
Location	Trials
United States	7

Trials by US State

Trials by US State for tetanus and diphtheria toxoids adsorbed
Location	Trials
North Carolina	5
Washington	1
Texas	1

Clinical Trial Progress for tetanus and diphtheria toxoids adsorbed

Clinical Trial Phase

Clinical Trial Phase for tetanus and diphtheria toxoids adsorbed
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	4

Clinical Trial Status

Clinical Trial Status for tetanus and diphtheria toxoids adsorbed
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1
Not yet recruiting	1

Clinical Trial Sponsors for tetanus and diphtheria toxoids adsorbed

Sponsor Name

Sponsor Name for tetanus and diphtheria toxoids adsorbed
Sponsor	Trials
Gary Archer Ph.D.	3
National Institute of Allergy and Infectious Diseases (NIAID)	1
Bristol-Myers Squibb	1

Sponsor Type

Sponsor Type for tetanus and diphtheria toxoids adsorbed
Sponsor	Trials
Other	5
Industry	2
NIH	1

Last updated: May 7, 2026

Clinical Trials Update, Market Analysis, and Projection for Tetanus and Diphtheria Toxoids Adsorbed (Td Adsorbed)

What is Td adsorbed and how is it used in the market?

Tetanus and diphtheria toxoids adsorbed (Td adsorbed) is a combined passive-immunogen vaccine product used to prevent tetanus and diphtheria. Commercially, Td products are used in routine and catch-up immunization for children and adults who need booster protection, with use expanding in wound management pathways for tetanus prevention depending on national practice. Market demand is driven by:

• Population coverage (routine boosters and catch-up)
• Immunization schedule adherence (national EPI schedules)
• Wound prevention protocols (tetanus prophylaxis in trauma care)
• Procurement cycles (tender-based vaccine buying by public and private payers)

Core commercial dynamic: Td adsorbed competes primarily within the “adult booster” slot against other formulations such as Td/Tdap combinations and regional alternative brands procured by national immunization programs.

---

Which clinical trial programs matter for Td adsorbed right now?

A Td adsorbed clinical-trials update depends on the existence of active development programs (new formulations, new carriers, new adjuvants, expanded-age indications, or process changes treated as clinically relevant). This answer requires a complete set of verifiable, current trial records and dates for Td adsorbed (or equivalent “tetanus and diphtheria toxoids, adsorbed” label expansions) across major registries.

No registry-backed, date-specific trial dataset for current Td adsorbed clinical activity is provided in the prompt, and producing a “clinical trials update” without sourced, record-level evidence would be inaccurate.

Result: No complete and accurate clinical-trials update can be produced under the data constraints.

---

What is the market size and structure for Td adsorbed?

A market analysis and projection requires at least one of the following evidence bases:

• A published market size forecast series (global and/or regional) with a defined product scope that explicitly includes Td adsorbed
• A country-level procurement and tender dataset for Td adsorbed
• Clear segment mapping that distinguishes Td adsorbed from adjacent products (Tdap, DT, TT, DTaP-containing combinations) using consistent definitions

The prompt provides no such market-sizing dataset or product scope definition. Without sourced market sizing inputs, it is not possible to produce a defensible quantitative market projection while maintaining accuracy.

Result: No complete and accurate Td adsorbed market analysis and projection can be produced under the data constraints.

---

Why Td adsorbed projections are sensitive to formulation and label definitions

Td adsorbed pricing and volume depend on product labeling and interchangeability, including:

• Formulation scope (Td vs Tdap; Td vs formulations with different antigen content)
• Indication scope (routine boosters vs wound management protocols)
• Geography (EPI schedules and adult coverage strategies)
• Tender structure (single-bid national procurement vs multi-vendor frameworks)

Any projection that mixes Td adsorbed with broader “tetanus/diphtheria vaccines” categories will misstate growth rates. Building a correct model requires a consistent numerator and denominator aligned to each source’s product definition.

Result: A projection cannot be constructed without those definitional anchors.

---

Actionable implications for R&D and investment (what can be concluded from fundamentals)

Even without registry- and market-sizing data, Td adsorbed is typically characterized by:

• Mature product class with incremental development focus (stability, manufacturing consistency, immunogenicity comparability)
• High regulatory scrutiny on lot consistency and antigen potency for toxoid vaccines
• Procurement-driven volume where price competition and tender wins dominate near-term revenue variability

For an operator evaluating investment or partnering:

• The highest-leverage opportunity usually sits in manufacturing reliability (supply continuity, QA performance, capacity ramp) and regulatory execution (label expansion, compatibility with national schedules).
• The biggest threat is schedule substitution by Tdap-inclusive strategies where reimbursement and procurement policies shift.

This is directional, but it is not a substitute for quantitative trial and market evidence.

---

Key Takeaways

• A complete, sourced clinical-trials update for Td adsorbed cannot be produced because the prompt contains no registry-backed trial records or date-specific program evidence.
• A complete, sourced market analysis and projection cannot be produced because the prompt contains no market-sizing series, procurement data, or product-scope definitions that isolate Td adsorbed.
• Td adsorbed demand is driven by EPI and booster coverage and is highly sensitive to policy substitution between Td and Tdap pathways, but quantitative forecasts require sourced datasets.

---

FAQs

1) Is Td adsorbed the same as Tdap?

No. Td adsorbed targets tetanus and diphtheria toxoids, while Tdap includes tetanus and diphtheria plus an acellular pertussis component. Formulations are not interchangeable for all schedules and tenders.

2) What endpoints usually support Td adsorbed label or formulation changes?

Trials typically rely on immunogenicity (antitoxin titers and seroprotection/seroresponse metrics) with bridging to existing licensed performance, consistent with toxoid vaccine regulatory expectations. Clinical endpoints are usually immunological rather than disease incidence.

3) What drives tender outcomes for Td adsorbed?

Public procurement usually prioritizes product quality documentation, consistent supply, price, and meeting tender specifications that can include antigen content, presentation, storage requirements, and schedules.

4) How does adult booster policy affect Td adsorbed revenue?

Adult booster coverage rates and whether adult programs prefer Td or switch toward Tdap drive volume. Changes to immunization guidance can shift demand between products.

5) Why are toxoid vaccines sensitive to manufacturing changes?

Toxoid potency, adsorption characteristics, and consistency across lots can materially affect immunogenicity. Regulatory review typically requires robust comparability evidence for process changes.

---

References

No sources were provided in the prompt, and no registry or market datasets were included for citation.